* Adial Pharmaceuticals Inc reported a quarterly adjusted loss of 38 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.18. The mean expectation of three analysts for the quarter was for a loss of 44 cents per share. Wall Street expected results to range from -50 cents to -32 cents per share.
* Reported revenue was zero; analysts expected zero.
* Adial Pharmaceuticals Inc's reported EPS for the quarter was a loss of 38 cents.
* The company reported a quarterly loss of $2.19 million.
* Adial Pharmaceuticals Inc shares had fallen by 0.8% this quarter and lost 46.7% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 6.5% in the last three months.
* In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Adial Pharmaceuticals Inc is $7.50 This summary was machine generated from LSEG data November 14 at 02:16 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.44 -0.38 Beat
Jun. 30 2024 -0.53 -0.59 Missed
Mar. 31 2024 -0.33 -0.62 Missed
Dec. 31 2023 -0.76 -1.35 Missed
Comments